HEALTH

Comparing New AD Drugs: How Well They Work and How Safe They Are

EuropeSun Nov 15 2026

People with moderate‑to‑severe atopic dermatitis often need systemic treatment. Since 2017, new drugs have become available. The European Medicines Agency has approved several biologics and JAK inhibitors for adults. The list includes dupilumab, tralokinumab, lebrikizumab, nemolizumab, upadacitinib, abrocitinib and baricitinib.

A review of 25 randomized trials looked at how well these drugs work. The main measure was EASI‑75, meaning a 75% drop in symptoms. Dupilumab gave results between 44% and 69%. Lebrikizumab hit 60.6%. Tr alokinumab ranged from 25% to 64%. Nemolizumab showed 49.1% in combo studies. Upadacitinib reached 73% at 16 weeks. Abrocitinib achieved 64.6% at 12 weeks. Baricitinib’s response was lower, 17.9% to 48%.

Safety was also tracked. Any side effect happened in 45% of patients on abrocitinib 100 mg, while nemolizumab had the highest rate at 82.46%. Serious events were rare across the board. Overall, the safety profile looks acceptable for short‑term use.

The findings suggest these drugs can help many adults quickly. However, trial designs differ and long‑term data are missing. Doctors should pick treatments based on each patient’s needs. More head‑to‑head studies and real‑world evidence will help refine choices.

actions